clinical trial · NCT05018286
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
VectivBio AG·phase3·active not recruiting·n = 158
Short Bowel SyndromeApraglutide
brief summary
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
started
Jul 13, 2021
primary completion
Oct 30, 2027
completion
Oct 30, 2027
last updated
Jul 2, 2025
detailed description
This is an international, multicenter, open label extension trial to collect further safety, tolerability, efficacy, durability, and clinical outcomes of apraglutide once weekly adminstration, for up to 208 weeks or until apraglutide is commercially available in the country, whichever comes first. Eligible subjects would be those who were trial subjects of TA799-007 or TA799-013 trials.
official title
An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol